BRIEF-Lilly says phase 3 MONARCH 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis

* Lilly announces phase 3 monarch 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.